MIP-1095 is under clinical development by Progenics Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MIP-1095’s likelihood of approval (LoA) and phase transition for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MIP-1095 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MIP-1095 overview

MIP-1095 is under development for the treatment of metastatic castration-resistant prostate cancer. The drug candidate is an iodine-131-labeled prostate-specific membrane antigen (PSMA) targeted small molecule radiotherapeutic. Iodine-131 is a beta-particle-emitting radionuclide that is capable of destroying tumor cells. It is administered through intravenous route.

Progenics Pharmaceuticals overview

Progenics Pharmaceuticals (Progenics) is a biopharmaceutical company.

Quick View MIP-1095 LOA Data

Report Segments
  • Innovator
Drug Name
  • MIP-1095
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.